BI breathes easy after Spiriva trumps LABAs in old school German HTA
This article was originally published in Scrip
Boehringer Ingelheim's top selling drug, Spiriva (tiotropium) offers additional benefit compared to placebo and long-acting beta-2 agonists (LABAs), says a report from IQWiG, Germany's Institute of Quality and Efficiency in Healthcare. The findings mark a more positive endorsement of the drug than the institute's previous report published in November, which concluded that Spiriva offered additional benefit in comparison only to one LABA, salmeterol.
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.